Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: XYZAL

Summary for Tradename: XYZAL

Suppliers: see list6
patent expirations by year for

Pharmacology for Tradename: XYZAL

Clinical Trials for: XYZAL

Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
Status: Completed Condition: Dermatitis; Eczema

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
Status: Completed Condition: Chronic Urticaria

Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Omnaris Versus Levocetirizine Phase 4 Study
Status: Completed Condition: Allergic Rhinitis

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism
Status: Terminated Condition: Rhinitis; Urticaria

Pharmacokinetic Study of Levocetirizine Oral Solution
Status: Completed Condition: Rhinitis, Allergic, Perennial and Seasonal

Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions
Status: Completed Condition: Fasting

Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
Status: Completed Condition: Perennial Allergic Rhinitis

Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
Status: Completed Condition: Rhinitis

Management of Pruritus With Xyzal in Atopic Dermatitis
Status: Completed Condition: Atopic Dermatitis; Pruritus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
levocetirizine dihydrochloride
SOLUTION;ORAL022157Jan 28, 2008RXYes5,698,558*PED<disabled>Y<disabled>
Ucb Inc
levocetirizine dihydrochloride
TABLET;ORAL022064May 25, 2007RXYes5,698,558*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: XYZAL

Drugname Dosage Strength RLD Submissiondate
levocetirizine dihydrochlorideOral Solution0.5 mg/mLXyzal1/14/2009
levocetirizine dihydrochlorideTablets5 mgXyzal12/17/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology